JP2019534853A - 認知症でない患者における神経保護薬としての、ω3脂肪酸、一酸化窒素放出化合物及びビタミンB12 - Google Patents
認知症でない患者における神経保護薬としての、ω3脂肪酸、一酸化窒素放出化合物及びビタミンB12 Download PDFInfo
- Publication number
- JP2019534853A JP2019534853A JP2019512889A JP2019512889A JP2019534853A JP 2019534853 A JP2019534853 A JP 2019534853A JP 2019512889 A JP2019512889 A JP 2019512889A JP 2019512889 A JP2019512889 A JP 2019512889A JP 2019534853 A JP2019534853 A JP 2019534853A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- composition
- individual
- dementia
- cognitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 65
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 title claims abstract description 64
- 235000019163 vitamin B12 Nutrition 0.000 title claims abstract description 64
- 239000011715 vitamin B12 Substances 0.000 title claims abstract description 64
- 229930003779 Vitamin B12 Natural products 0.000 title claims abstract description 63
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 32
- 229940012843 omega-3 fatty acid Drugs 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title claims description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title description 15
- 239000006014 omega-3 oil Substances 0.000 title description 5
- 239000004090 neuroprotective agent Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 123
- 230000032683 aging Effects 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 64
- 230000001149 cognitive effect Effects 0.000 claims abstract description 45
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 42
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 29
- 239000002840 nitric oxide donor Substances 0.000 claims abstract description 29
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 27
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 21
- 230000008901 benefit Effects 0.000 claims abstract description 20
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 19
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 19
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000019159 vitamin B9 Nutrition 0.000 claims abstract description 16
- 239000011727 vitamin B9 Substances 0.000 claims abstract description 16
- 229930003761 Vitamin B9 Natural products 0.000 claims abstract description 15
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 5
- 208000024806 Brain atrophy Diseases 0.000 claims abstract description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims abstract description 5
- 206010057249 Phagocytosis Diseases 0.000 claims abstract description 5
- 230000003959 neuroinflammation Effects 0.000 claims abstract description 5
- 230000008782 phagocytosis Effects 0.000 claims abstract description 5
- 230000000946 synaptic effect Effects 0.000 claims abstract description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 43
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 24
- 208000010877 cognitive disease Diseases 0.000 claims description 23
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 21
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 19
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 19
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 19
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 19
- 210000004556 brain Anatomy 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 15
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 14
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 14
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 14
- 229960002173 citrulline Drugs 0.000 claims description 14
- 235000013477 citrulline Nutrition 0.000 claims description 14
- 230000006999 cognitive decline Effects 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 229960001231 choline Drugs 0.000 claims description 10
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 10
- 230000015654 memory Effects 0.000 claims description 10
- 210000002569 neuron Anatomy 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 229960003495 thiamine Drugs 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- 230000003931 cognitive performance Effects 0.000 claims description 7
- 238000012423 maintenance Methods 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 230000019771 cognition Effects 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000003925 fat Substances 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 229930003756 Vitamin B7 Natural products 0.000 claims description 4
- 229960004874 choline bitartrate Drugs 0.000 claims description 4
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 235000011912 vitamin B7 Nutrition 0.000 claims description 4
- 239000011735 vitamin B7 Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- 229930003571 Vitamin B5 Natural products 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 210000004958 brain cell Anatomy 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 235000011649 selenium Nutrition 0.000 claims description 3
- 229940091258 selenium supplement Drugs 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- 239000011675 vitamin B5 Substances 0.000 claims description 3
- 235000009492 vitamin B5 Nutrition 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000007996 neuronal plasticity Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 230000003920 cognitive function Effects 0.000 description 11
- 235000019152 folic acid Nutrition 0.000 description 9
- 239000011724 folic acid Substances 0.000 description 9
- 235000019156 vitamin B Nutrition 0.000 description 9
- 239000011720 vitamin B Substances 0.000 description 9
- 230000003930 cognitive ability Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 208000028698 Cognitive impairment Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- 229930003270 Vitamin B Natural products 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 235000021196 dietary intervention Nutrition 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229940014144 folate Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000003557 neuropsychological effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036995 brain health Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 230000001073 episodic memory Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- AUNGANRZJHBGPY-MBNYWOFBSA-N 7,8-dimethyl-10-[(2R,3R,4S)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4-dione Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-MBNYWOFBSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000934858 Homo sapiens Breast cancer type 2 susceptibility protein Proteins 0.000 description 1
- 101000848289 Homo sapiens FAD synthase region Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 1
- 241001481825 Morone saxatilis Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000269980 Pleuronectidae Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 101000848282 Siganus canaliculatus Acyl-CoA Delta-6 desaturase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003215 anti-neuroinflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000008455 cerebrovascular function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004788 choline alfoscerate Drugs 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 230000037410 cognitive enhancement Effects 0.000 description 1
- 230000004633 cognitive health Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013538 functional additive Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012030 stroop test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012034 trail making test Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000021467 vitamin B7(Biotin) Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
[0030]
[0032]以下、いくつかの定義を示す。しかしながら定義が以下の「実施形態」の項にある場合もあり、上記の見出し「定義」は、「実施形態」の項におけるそのような開示が定義ではないことを意味するものではない。
[0046]本開示の一態様において、組成物は、ω3脂肪酸と、一酸化窒素放出化合物と、大量のビタミンB12を提供するビタミンB群と、の組み合わせを含み、好ましくは、組成物は、認知症ではない個体において認知的加齢を低減させ、及び/又は認知能力を改善するのに効果的な量の組み合わせを含む。かかる組成物は、好ましくは上記したような高ビタミンB12濃度を有する。別の態様においては、認知症ではない個体の認知的加齢を低減させ及び/又は認知能力を改善するための方法は、該個体に有効量の組成物を(例えば経口的に)投与するステップを含む。組成物は、好ましくは本願明細書に定義されるものである。
[0070]
[0072]以下の非限定的な実施例は、認知症ではない個体において認知的加齢を低減させるための、本開示により提供される実施態様における組成物を例示する。
[0074]試験実施の主な目的を、神経心理学的評価の合成得点によって測定される認知機能低下を予防するための、実施例1に記載される組成物による4年間の介入の有効性を示すこととする。全試験集団は、70歳以上の主観的に記憶力に関する懸念を有する認知症ではない成人から構成し、そのうち、ベースラインにおいて低DHA状態(赤血球のω3指数<4.8%)により定義される試験集団のサブグループと、ベースラインにおいて0.5の臨床的認知症尺度(CDR)を有する試験集団の他のサブグループを設ける。
(i)BPB介入に関連する血漿栄養分濃度及びバイオマーカー(例えばホモシステイン、赤血球細胞(RBC)のDHA状態)に対する治療効果;
(ii)合成得点において使用される試験結果の個別的な分析により測定される治療効果、並びに追加神経心理学的試験のスコア(MMSE総スコア);
(iii)トレイルメイキングテスト、ロジカルメモリテスト、文字流暢性(Letter Fluency)、ストループ(Stroop)試験及び数唱(Digit Span);
(iv)CDR−SOB(Clinical Dementia Rating−Sum of Boxes)スコアの変化により測定される治療効果、及び軽症認知障害(MCI)及び認知症への変換率;
(v)参加者の結果報告に基づく、機能及び生活の質に対する治療効果:認知機能インスツルメント(Cognitive Function Instrument);EQ−5D−5L、及び応用認知−能力インスツルメント(Applied Cognition−ABilities instruments);
(vi)以下の被験者の特徴により定義されるサブグループにおける治療効果:
ベースラインにおける高血漿ホモシステイン濃度(血漿ホモシステイン≧12μmol/L)、ベースラインにおけるCAIDE(心臓血管リスク因子、老化及び認知症)リスクスコア、ベースラインにおけるアミロイドPETスキャンによるアミロイド陽性、及び遺伝子型。
(i)MRIに基づく全脳及び海馬の萎縮、並びに総白質の超強度の蓄積、動脈スピンラベリング(Arterial Spin LaBeling)によるイメージング、試験集団(アーム当たり最大500人の被験者)の代表的サブセットにおける安静時fMRI(Resting State fMRI);(ii)試験集団(アーム当たり最大500人の被験者)の代表的サブセットにおけるアミロイド/タウPET;(iii)血漿マーカー、すなわち血漿BDNF、血漿Aβ40〜42及びタウタンパク質、非対称ジメチルアルギニン、ホモシステイン、血漿炎症マーカー(sCAMs、E−セレクチン、TNFα、IL1、IL6、IL10、CRP)、並びに酸化ストレスの血漿マーカー(酸化型低比重リポタンパク質(oxLDL)、F2−イソプロスタン)。
[0086]以下の非限定的な実施例は、培養したヒト誘導多能性幹細胞由来の神経細胞における細胞膜流動性を増加させるための、本明細書で定義される組成物の使用を支持する、実験例である。
[0088]ヒト誘導多能性幹細胞由来の神経細胞、及び付属の増殖培地は、Cellular Dynamics International社から購入した。製造業者(Cellular Dynamics International社)のプロトコルに従い神経細胞を培養した。製造元のプロトコルに従い、PLO/ラミニンでコーティングした培養容器(96ウエルプレート、μ−clear、Greiner社)に、100,000〜150,000個/cm2の密度で神経細胞をプレーティングし、インキュベーター(37℃、5%のCO2)にて維持した。維持培地の50%を週に2回交換した。
[0092]データを、ボックスプロット(最低−最高)として図1に示す。一方向ANOVA及びTukeyの多重比較試験を用いて統計的有意性を算出した。P=0.05未満を有意とみなした。図1からわかるように、DHA+EPAと高濃度のB12及びシトルリンとの組み合わせ(T6high)は、細胞膜流動性を顕著に高める。
Claims (34)
- 認知的加齢の低減、治療又は予防を必要とするか、あるいは認知的加齢のリスクがある認知症ではない個体の認知的加齢を低減、治療又は予防する方法であって、ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12とを含む組成物を治療的に有効な量で前記個体に投与するステップを含み、前記組成物が、1日当たりの推奨所要量(RDA)の50〜500倍のビタミンB12を提供する一日用量で投与される、方法。
- 前記一日用量が、1日当たりにRDAの約150〜300倍、好ましくは1日当たりにRDAの200倍のビタミンB12を提供する、請求項1に記載の方法。
- 前記個体が高齢成体である、請求項1又は2に記載の方法。
- 前記個体が老齢のヒトである、請求項1〜3のいずれか一項に記載の方法。
- 前記組成物が、前記個体に少なくとも1ヶ月間、毎日経口投与される、請求項1〜4のいずれか一項に記載の方法。
- 前記一酸化窒素放出化合物が、シトルリンを含む、請求項1〜5のいずれか一項に記載の方法。
- 前記ω3脂肪酸が、ドコサヘキサエン酸、エイコサペンタエン酸及びそれらの混合物からなる群から選択される脂肪酸を含む、請求項1〜6のいずれか一項に記載の方法。
- 前記組成物が、ビタミンB1、ビタミンB2、ビタミンB3、ビタミンB5、ビタミンB6、ビタミンB7及びビタミンB9からなる群から選択される1種以上の追加のビタミンB類を含む、請求項1〜7のいずれか一項に記載の方法。
- 前記1種以上の追加のビタミンB類が、少なくともビタミンB6を含む、請求項8に記載の方法。
- 前記1種以上の追加のビタミンB類が、少なくともビタミンB9を含む、請求項8に記載の方法。
- 前記1種以上の追加のビタミンB類が、少なくともビタミンB6及びビタミンB9を含む、請求項8に記載の方法。
- 前記組成物が、ビタミンC、ビタミンD、ビタミンE、セレン及びコリンからなる群から選択される1つ以上の抗酸化剤、好ましくはコリン重酒石酸塩を含む、請求項1〜11のいずれか一項に記載の方法。
- 前記個体がベースラインにおいて低DHA状態を有する、請求項1〜12のいずれか一項に記載の方法。
- 前記個体がベースラインにおいて0.5の臨床的認知症尺度(CDR)を有する、請求項1〜13のいずれか一項に記載の方法。
- 前記個体がベースラインにおいて少なくとも12μmol/Lの低血漿ホモシステイン濃度を有する、請求項1〜14のいずれか一項に記載の方法。
- 前記個体がベースラインにおいて10〜15の心臓血管リスク因子、老化及び認知症(Cardiovascular Risk Factors,Aging and Dementia(CAIDE))リスクスコアを有する、請求項1〜15のいずれか一項に記載の方法。
- 前記個体がベースラインにおけるPETアミロイドスキャンでアミロイド陽性である、請求項1〜16のいずれか一項に記載の方法。
- 前記個体が、認知機能低下のリスクを示す遺伝子型を有する、請求項1〜17のいずれか一項に記載の方法。
- 前記投与が、神経細胞の細胞膜流動性の改善、神経可塑性及び活性の刺激、抗炎症性の改善、認知パフォーマンスの支持又は維持、脳パフォーマンスの支持又は維持、脳の加齢の緩徐化、活発な意識及び脳の適応性の支持、健康な脳の支持又は維持、記憶力の強化、実行機能の強化、注意力の強化、健全な認知の維持、脳細胞の健康の維持をもたらす、請求項1〜18のいずれか一項に記載の方法。
- 認知的加齢の低減、治療又は予防を必要とするか、あるいは認知的加齢のリスクがある認知症ではない個体の認知的加齢を低減、治療又は予防する方法であって、ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12とを含む組成物を治療的に有効な量で前記個体に投与するステップを含み、前記組成物が、1日当たりに約0.4mg〜約1.0mgのビタミンB12を提供する一日用量で投与される、方法。
- 脳萎縮の減少、シナプシス数の増加又は維持、アミロイド−β食作用の増加又は維持、並びに神経炎症の減少からなる群から選択される利益のうちの1つ以上を、当該利益を必要とする認知症ではない個体において得る方法であって、ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12とを含む組成物を治療的に有効な量で前記個体に投与するステップを含み、前記組成物が、1日当たりにビタミンB12の推奨所要量(RDA)の50〜500倍を提供する一日用量で投与される、方法。
- 前記一日用量が、1日当たりにRDAの約200倍の前記ビタミンB12を提供する、請求項20又は21に記載の方法。
- 前記一酸化窒素放出化合物がシトルリンを含み、前記ω3脂肪酸が、ドコサヘキサエン酸、エイコサペンタエン酸及びそれらの混合物からなる群から選択される脂肪酸を含む、請求項20又は21に記載の方法。
- ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12との組み合わせを含む組成物であって、前記組成物の一日用量が、1日当たりに推奨所要量(RDA)の50〜500倍のビタミンB12を提供し、前記組成物が認知症ではない個体の認知的加齢を低減させるのに効果的な量の組み合わせを含む、組成物。
- 前記組成物が、前記組成物に対して1〜50重量%の量のω3脂肪酸と、前記組成物に対して1〜20重量%の量の一酸化窒素放出化合物と、1日当たりに推奨所要量(RDA)の50〜500倍の量のビタミンB12と、を含む請求項24に記載の組成物。
- 前記組成物が、タンパク質、炭水化物、脂肪、及びこれらの組み合わせからなる群から選択される成分を含む食品製品である、請求項24又は25に記載の組成物。
- 前記組成物が製薬上許容できる担体、希釈剤及び賦形剤からなる群から選択される成分を含む医薬組成物である、請求項24又は25に記載の組成物。
- 認知的加齢の低減、治療又は予防を必要とするか、あるいは認知的加齢のリスクがある認知症ではない個体において、認知的加齢を低減、治療又は予防するために用いられる、請求項24〜27のいずれか一項に記載の組成物。
- 神経細胞の細胞膜流動性の改善、神経可塑性及び活性の刺激、抗炎症性の改善、認知パフォーマンスの支持又は維持、脳パフォーマンスの支持又は維持、脳の加齢の緩徐化、活発な意識及び脳の適応性の維持、健康な脳の支持又は維持、記憶力の強化、実行機能の強化、注意力の強化、健全な認知の維持、脳細胞の健康の維持に用いられる、請求項24〜28のいずれか一項に記載の組成物。
- 認知症ではない個体の認知的加齢を低減させるための食品組成物を製造する方法であって、タンパク質、炭水化物及び脂肪からなる群から選択される少なくとも1つの成分に、ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12との組み合わせを有効量で添加するステップを含み、前記食品組成物が、1日当たりに推奨所要量(RDA)の50〜500倍のビタミンB12を提供する、方法。
- 認知症ではない個体の認知的加齢を低減させるための医薬組成物を製造する方法であって、製薬上許容できる担体、希釈剤及び賦形剤からなる群から選択される少なくとも1つの成分に、ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12との組み合わせを有効量で添加するステップを含み、前記医薬組成物が、1日当たりに推奨所要量(RDA)の50〜500倍のビタミンB12を提供する、方法。
- 認知症のリスクがある個体における認知症を予防する方法であって、ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12とを含む組成物を治療的に有効な量で前記個体に投与するステップを含み、前記組成物が、1日当たりに推奨所要量(RDA)の50〜500倍のビタミンB12を提供する一日用量で投与される、方法。
- 予防される前記認知症が、アルツハイマー病、血管性認知症、レヴィー小体認知症、前頭側頭型認知症及びそれらの組み合わせからなる群から選択される、請求項32に記載の方法。
- 認知症ではない個体において認知能力を改善する方法であって、ω3脂肪酸と、一酸化窒素放出化合物と、ビタミンB12とを含む組成物を治療的に有効な量で前記個体に投与するステップを含み、前記組成物が、1日当たりに推奨所要量(RDA)の50〜500倍のビタミンB12を提供する一日用量で投与される、方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662401443P | 2016-09-29 | 2016-09-29 | |
US62/401,443 | 2016-09-29 | ||
US201762484119P | 2017-04-11 | 2017-04-11 | |
US201762484156P | 2017-04-11 | 2017-04-11 | |
US62/484,156 | 2017-04-11 | ||
US62/484,119 | 2017-04-11 | ||
PCT/EP2017/074729 WO2018060395A1 (en) | 2016-09-29 | 2017-09-29 | Omega 3 fatty acids, no releasing compound and vitamin b12 as neuroprotectant in patients with no dementia |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019534853A true JP2019534853A (ja) | 2019-12-05 |
Family
ID=60009613
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019512869A Pending JP2019530665A (ja) | 2016-09-29 | 2017-09-29 | 認知症ではない患者における神経保護薬としての、ω3脂肪酸及びコリン |
JP2019512889A Pending JP2019534853A (ja) | 2016-09-29 | 2017-09-29 | 認知症でない患者における神経保護薬としての、ω3脂肪酸、一酸化窒素放出化合物及びビタミンB12 |
JP2022175336A Pending JP2023011800A (ja) | 2016-09-29 | 2022-11-01 | 認知症ではない患者における神経保護薬としての、ω3脂肪酸及びコリン |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019512869A Pending JP2019530665A (ja) | 2016-09-29 | 2017-09-29 | 認知症ではない患者における神経保護薬としての、ω3脂肪酸及びコリン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022175336A Pending JP2023011800A (ja) | 2016-09-29 | 2022-11-01 | 認知症ではない患者における神経保護薬としての、ω3脂肪酸及びコリン |
Country Status (9)
Country | Link |
---|---|
US (2) | US11813233B2 (ja) |
EP (3) | EP3518919A1 (ja) |
JP (3) | JP2019530665A (ja) |
CN (2) | CN109689041A (ja) |
AU (2) | AU2017336292B2 (ja) |
BR (2) | BR112019004041A2 (ja) |
CA (2) | CA3034684A1 (ja) |
MX (3) | MX2019003285A (ja) |
WO (2) | WO2018060396A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7270546B2 (ja) * | 2017-04-11 | 2023-05-10 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 個体における認知的加齢を特定及び軽減するためのオメガ3脂肪酸及びビタミンdレベル |
CN115443074A (zh) * | 2021-04-06 | 2022-12-06 | 德国生物分子研究公司 | 营养配制品 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020182196A1 (en) * | 2001-04-19 | 2002-12-05 | Mccleary Edward Larry | Composition and method for normalizing impaired or deteriorating neurological function |
JP2011508773A (ja) * | 2008-01-04 | 2011-03-17 | ネステク ソシエテ アノニム | 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用 |
US20140271844A1 (en) * | 2013-03-15 | 2014-09-18 | Nitromega Corp. | Compositions containing nitro fatty acids |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
IL158552A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
WO2006127627A2 (en) * | 2005-05-23 | 2006-11-30 | Massachusetts Institute Of Technology | Compostions containing pufa and/or uridine and methods of use thereof |
US20080003330A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Infant formulas for early brain development |
WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
AU2008307494B2 (en) * | 2007-10-04 | 2013-09-05 | Société des Produits Nestlé S.A. | Compositions and methods for enhancing cognitive function |
AU2009334476B2 (en) * | 2008-12-31 | 2013-08-29 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
EP2440201A1 (en) * | 2009-06-10 | 2012-04-18 | Energy4life Ag | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders |
WO2011133580A1 (en) * | 2010-04-19 | 2011-10-27 | Back Bay Scientific Llc | Use of drugs that activate p2y receptors to enhance synaptogenesis |
WO2014027882A1 (en) * | 2012-08-13 | 2014-02-20 | N.V. Nutricia | Product and method for supporting uridine homeostasis |
WO2014151364A1 (en) * | 2013-03-15 | 2014-09-25 | Buck Institute For Research On Aging | Improved cognitive supplements |
CN107708446A (zh) | 2015-06-22 | 2018-02-16 | 雀巢产品技术援助有限公司 | 用于增强动物体内神经形成的组合物和方法 |
-
2017
- 2017-09-29 AU AU2017336292A patent/AU2017336292B2/en active Active
- 2017-09-29 AU AU2017336291A patent/AU2017336291B2/en active Active
- 2017-09-29 JP JP2019512869A patent/JP2019530665A/ja active Pending
- 2017-09-29 CA CA3034684A patent/CA3034684A1/en active Pending
- 2017-09-29 CN CN201780055067.7A patent/CN109689041A/zh active Pending
- 2017-09-29 CN CN201780054353.1A patent/CN109661227A/zh active Pending
- 2017-09-29 WO PCT/EP2017/074731 patent/WO2018060396A1/en unknown
- 2017-09-29 EP EP17778254.7A patent/EP3518919A1/en not_active Withdrawn
- 2017-09-29 MX MX2019003285A patent/MX2019003285A/es unknown
- 2017-09-29 MX MX2019002827A patent/MX2019002827A/es unknown
- 2017-09-29 EP EP17780365.7A patent/EP3518917A1/en not_active Withdrawn
- 2017-09-29 BR BR112019004041A patent/BR112019004041A2/pt active Search and Examination
- 2017-09-29 EP EP20203878.2A patent/EP3811938A1/en active Pending
- 2017-09-29 JP JP2019512889A patent/JP2019534853A/ja active Pending
- 2017-09-29 US US16/336,294 patent/US11813233B2/en active Active
- 2017-09-29 WO PCT/EP2017/074729 patent/WO2018060395A1/en unknown
- 2017-09-29 CA CA3034187A patent/CA3034187A1/en active Pending
- 2017-09-29 US US16/336,308 patent/US10821130B2/en active Active
- 2017-09-29 BR BR112019004055-2A patent/BR112019004055A2/pt active Search and Examination
-
2019
- 2019-03-11 MX MX2021015377A patent/MX2021015377A/es unknown
-
2022
- 2022-11-01 JP JP2022175336A patent/JP2023011800A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020182196A1 (en) * | 2001-04-19 | 2002-12-05 | Mccleary Edward Larry | Composition and method for normalizing impaired or deteriorating neurological function |
JP2011508773A (ja) * | 2008-01-04 | 2011-03-17 | ネステク ソシエテ アノニム | 不飽和脂肪酸及び酸化窒素放出化合物を含む組成物、並びに認知機能及び関連の機能を高めるためのそれらの使用 |
US20140271844A1 (en) * | 2013-03-15 | 2014-09-18 | Nitromega Corp. | Compositions containing nitro fatty acids |
Non-Patent Citations (1)
Title |
---|
NEUROCHEM INT., vol. 58, no. 3, JPN6022009759, 2011, pages 321 - 329, ISSN: 0004727102 * |
Also Published As
Publication number | Publication date |
---|---|
CA3034684A1 (en) | 2018-04-05 |
US11813233B2 (en) | 2023-11-14 |
AU2017336292A1 (en) | 2019-02-21 |
CN109661227A (zh) | 2019-04-19 |
EP3518919A1 (en) | 2019-08-07 |
WO2018060395A1 (en) | 2018-04-05 |
JP2019530665A (ja) | 2019-10-24 |
US20200046660A1 (en) | 2020-02-13 |
CA3034187A1 (en) | 2018-04-05 |
US10821130B2 (en) | 2020-11-03 |
EP3518917A1 (en) | 2019-08-07 |
BR112019004055A2 (pt) | 2019-05-21 |
MX2019002827A (es) | 2019-07-15 |
JP2023011800A (ja) | 2023-01-24 |
MX2019003285A (es) | 2019-11-11 |
AU2017336292B2 (en) | 2023-08-03 |
AU2017336291A1 (en) | 2019-02-21 |
BR112019004041A2 (pt) | 2019-05-28 |
MX2021015377A (es) | 2022-03-02 |
EP3811938A1 (en) | 2021-04-28 |
US20190209601A1 (en) | 2019-07-11 |
AU2017336291B2 (en) | 2023-01-12 |
CN109689041A (zh) | 2019-04-26 |
WO2018060396A1 (en) | 2018-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5537809B2 (ja) | 脳機能を維持するための組成物及び方法 | |
JP2023011800A (ja) | 認知症ではない患者における神経保護薬としての、ω3脂肪酸及びコリン | |
US20230310488A1 (en) | Compositions and methods that attenuate cognitive aging in individuals who do not have dementia | |
EP3388061A1 (en) | Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia | |
US20230310360A1 (en) | Mct formulations for improving cognitive functions | |
CA3235524A1 (en) | Compositions and methods using a combination of nutrients to support cognition and emotional health in a mammal | |
WO2018189022A1 (en) | Compositions and methods that attenuate cognitive aging in individuals who do not have dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190614 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220315 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240502 |